liposomal bpc 157 BPC-157 Peptide Therapy ✨ January Product Spotlight: Oral

Zakhari, S

In August 2009, the Centers for Medicare and Medicaid Services concluded, "the available evidence does not demonstrate that pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness improves health outcomes in Medicare beneficiaries." [95] A 2014 meta-analysis showed that using genotype-based dosing did not confer benefit in terms of time within therapeutic range, excessive anticoagulation (as defined by INR greater than 4), or a reduction in either major bleeding or thromboembolic events

ClinicalTrials.gov does not list any active or completed IGF-1 LR3 efficacy or safety study

That was over a year ago, we inject every second day and have never looked back

Fang, S., Niu, Y., Zhang, W., Zhang, Y., Yu, L., Zhang, Y., & Li, X